A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Phase of Trial: Phase III
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Mirikizumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms AMAN; LUCENT-1
- Sponsors Eli Lilly and Company
- 02 Nov 2018 Planned primary completion date changed from 23 Jun 2020 to 7 Sep 2020.
- 18 Jul 2018 Planned primary completion date changed from 7 Sep 2020 to 23 Jun 2020.
- 23 Jun 2018 Status changed from not yet recruiting to recruiting.